fda warning letters glp-1 compounders october 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading February 17, 2026: Pennsylvania compounding

Each component was identified through clinician-documented diagnoses and corresponding diagnostic codes within the electronic medical record

Retatrutide : Phase 2 completed for obesity (NEJM 2023, 338 patients) and Phase 2a for MASH

Z., & McLemore, M

I immediately noticed how well my skin absorbed the product

In reality, they are most effective when used as part of a comprehensive strategy that addresses the root causes of weight gain

In the SURMOUNT-1 trial, participants without diabetes lost an average of 15-20% of their body weight over 72 weeks at the 10 mg and 15 mg doses, though results may vary in different populations